Eyeing a rivalry with Roche and a new cancer asset slated to hit the markets next year, Bristol Myers Squibb is picking up Turning Point Therapeutics in a $4.1 billion deal.
A five-hospital acquisition between HCA Healthcare and Steward Health Care as well as a merger between RWJBarnabas Health and Saint Peter's Healthcare System are on the federal regulator's chopping block.
This week on "The Top Line," we discuss our special report on the top 20 drugs by 2021 sales, and it is no surprise that products that fight COVID-19 dominated the biopharma landscape. We also talk about this weekend’s ASCO meeting and the week's other big headlines. Plus, we have bloopers!
The White House announced the rollout of COVID-19 vaccinations for kids under 5 could start as early as June 21, with primary care doctors playing a big role.
Back in 2013, AbbVie and Johnson & Johnson’s Imbruvica got its very first FDA go-ahead, which was for previously treated mantle cell lymphoma. Now, the company is trumpeting a trial win in newly diagnosed patients despite not showing a life-extension advantage.
Merck KGaA's North American healthcare business, EMD Serono, is discontinuing a clinical trial for a med once considered a star in its oncology program, but an interim analysis has the company changing tactics.
A device that’s meant to clear out and expand the lungs may actually go too far, resulting in a potentially dangerous decrease in oxygen levels, Baxter said this week.
The latest Medicare Trustees report projects the Hospital Insurance Trust Fund will run out of money in 2028, two years later compared to last year's report.
This could be good news, or bad news. Amylyx Pharmaceuticals has received notice from the FDA that the decision date for its amyotrophic lateral sclerosis drug has been extended.
BD will begin rolling out its latest technology for sorting and characterizing the myriad cells that make up the human body, with a speed and clarity that the company says could help identify new types of cells and the roles they play in life and disease.
